EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions

Surim Meagan Kim, Wonsuk Shin, A-Young Yang, Anhye Kim, Yil-Seob Lee, Jaejin Na, Jae Min Cho, Seoyeon Yoon, Hyounggyoon Yoo

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-026-04986-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Surim Meagan Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: CHA University School of Medicine, 120 Hyeryong-Ro, Pocheon-Si, Gyeonggi-Do, Republic of Korea. Hauptthemen laut MEDLINE: Metformin, Hypoglycemic Agents, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Daewoong Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enavogliflozin is a sodium‒glucose cotransporter 2 inhibitor that can be administered in combination with metformin in patients with type 2 diabetes mellitus. This study aimed to compare the pharmacokinetics (PKs) between the fixed-dose combination (FDC) and the corresponding loose combination of enavogliflozin 0.3 mg and metformin 1000 mg. A randomized, open-label, 2-sequence, 4-period crossover study with a single oral dose was conducted in healthy subjects. Subjects received either the FDC or the corresponding loose combination of enavogliflozin 0.3 mg and metformin hydrochloride (HCl) 1000 mg in fasting and fed states. Serial blood samples were collected up to 72 h post-dose. Forty-four subjects were enrolled, and 37 subjects completed the study. In the fasting state, the geometric mean ratios (GMRs) (90% confidential interval (CI)) of the maximum plasma concentration (Cmax) and the area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast) of the FDC to those of the corresponding loose combination were 1.03 (0.97-1.10) and 1.08 (1.03-1.13), respectively. The GMRs (90% CI) of the metformin Cmax and AUClast of the FDC to those of the corresponding loose combination were 1.10 (1.01-1.19) and 1.05 (1.00-1.11), respectively. In a high-fat-fed state, the GMRs (90% CI) of the enavogliflozin Cmax and AUClast of the FDC to those of the corresponding loose combination were 0.88 (0.82-0.93) and 1.03 (0.98-1.09), respectively. The GMRs (90% CI) of the metformin Cmax and AUClast of the FDC to those of the corresponding loose combination were 1.01 (0.98-1.05) and 1.00 (0.97-1.04), respectively. All the results were within the conventional bioequivalence range (0.80-1.25). There were no deaths, serious adverse events in fasting high-fat-fed states. The FDC of enavogliflozin 0.3 mg and metformin HCl and the corresponding loose combination were pharmacokinetically equivalent without safety concerns in fasting and high-fat-fed states. The FDC can be an alternative option for combination therapy with enavogliflozin and metformin HCl with improved compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminHypoglycemic AgentsBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsHumansCross-Over StudiesMaleAdultFastingFemaleDrug CombinationsYoung AdultArea Under CurveMiddle AgedFood-Drug InteractionsAdministration, OralBenzofurans

Stichwörter der Autor:innen

EnavogliflozinExtended-release tabletFixed-dose combinationMetforminPharmacokinetics

Substanzen

MetforminHypoglycemic AgentsDrug CombinationsBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsEnavogliflozinBenzofurans

Autor:innen und Institutionen

  • CHA University School of Medicine, 120 Hyeryong-Ro, Pocheon-Si, Gyeonggi-Do, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea.
  • Department of Physiology, CHA University School of Medicine, Seongnam-Si, Gyeonggi-Do, Republic of Korea.
  • Department of Pharmacology, CHA University School of Medicine, Seongnam-Si, Gyeonggi-Do, Republic of Korea.
  • Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea. hgyoo0317@cha.ac.kr.

Förderung

  • Daewoong Pharmaceutical Company

Zitieren

APA

Kim, S. M., Shin, W., Yang, A. Y., Kim, A., Lee, Y. S., Na, J., Cho, J. M., Yoon, S., & Yoo, H. (2026). Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-04986-7

Vancouver

Kim SM, Shin W, Yang AY, Kim A, Lee YS, Na J, et al. Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-04986-7

BibTeX
@article{Kim2026,
  author = {Kim, Surim Meagan and Shin, Wonsuk and Yang, A-Young and Kim, Anhye and Lee, Yil-Seob and Na, Jaejin and Cho, Jae Min and Yoon, Seoyeon and Yoo, Hyounggyoon},
  title = {Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-026-04986-7}
}
Kostenlos starten →